Elevance Health (ELV) underwent a 17% surge in share price prompting thoughts about its true value. Major financial players like Strs Ohio and Fisher Funds Management LTD offloaded their shares, while others like Assetmark Inc. and Whalen Wealth Management accumulated more. A bullish sentiment was seen on Q3 projected figures and better-than expected sales growth despite a drop in memberships. Analysts estimated a decline in ELV's earnings, decreasing optimism. Q3 earnings report demonstrated reduction in net profit margin and earnings growth prospects challenged by declining margins, but JP Morgan forecasted a strong price appreciation. However, due to unforeseeable Medicaid troubles which trimmed outlook, and some ELV insiders selling $6.7m worth of stock, share prices dropped significantly turning aggregate investor sentiment bearish. Projections mainly rest on ACA subsidy uncertainties and the potential of the value-based care strategy. Several analysts including UBS, Bernstein, and Wells Fargo maintained a buy rating with divergent target prices.
Elevance Health ELV News Analytics from Wed, 02 Jul 2025 07:00:00 GMT to Sat, 01 Nov 2025 11:01:12 GMT -
Rating 7
- Innovation 5
- Information 6
- Rumor 4
